BJA: Acute kidney injury with heart surgery: double-blind randomized placebo-controlled trial

!---- Background and Objective This study is designed to assess whether intravenous cydinaric acid can prevent acute kidney injury in patients at high risk of in vitro circulatory heart surgeryMethod We conducted a double-blind randomized controlled trial at an independent tertiary medical center in the United Kingdom, in which adult patients with an increased risk of acute kidney injury after heart surgery were randomized intravenousinuated 12.5mg-kg-1 sedinafi at the beginning of surgery, with infusion time exceeding 150min, or intravenous infusion of 5% glucosethe main result ofwas the determination of serum creatinine values at 6 points in random groupingthe preliminary analysis of the use of linear mixed effect model, adjust the stratification variables, baseline estimation of the glomerular filtration rate and surgical processsecondary outcomes are clinical events and potential disease mechanismsperformance assessment is expressed in an average difference (MDs) or 95% CI advantage ratioresults in the results of the trial included random patients who underwent in vitro circulatory lower valve surgery or valve surgery combined with coronary artery bypass transplants between May 2015 and June 2018the non-group of Sitina included 60 patients and the placebo control group 69 patientsthere was no statistical difference in serum creatinine values between the two groups(MD: 0.88 smolL-1 (-5.82, 7.59))a significant increase in the score of non-group multi-organ dysfunction in Sitina (MD: 0.54 (0.02, 1.07); P-0.044)there was no significant difference in secondary results between the two groupsand biomarkers for kidney damage, endothelial function, and activation of inflammatory cellsconcluded that the above results do not support the non-protective kidney function of intravenous lysina in adult heart surgery